AvertD

AvertD® stands apart as the first and only U.S. Food and Drug Administration-authorized genetic test for assessing Opioid Use Disorder (OUD) risk. Backed by studies using DSM-5 clinical diagnoses, AvertD® provides healthcare providers with an objective and clinically validated tool to guide decisions for patients prescribed short-term oral opioids.

This is the gold standard of genetic testing, setting a new benchmark for innovation in opioid safety. Learn how AvertD® can enhance shared decision-making: https://avertdtest.com/

~1 in 6 patients who have an Elevated Genetic Risk may develop OUD after taking oral opioids for acute pain. AvertD® identifies genetic factors associated with an elevated risk of developing opioid use disorder (OUD). This FDA-approved test is rooted in rigorous research, providing healthcare providers with actionable insights to guide safer, more personalized pain management decisions.

Understanding an elevated risk doesn’t mean a patient will develop OUD — it’s about empowering patients and providers to make informed choices before opioids are prescribed.

Learn more about the science behind AvertD® and how it’s shaping the future of preventive care: https://avertdtest.com/

As many kick off the year with fitness goals, we are reminded and mindful of the risks associated with injuries that can occur while being active. For some, significant injuries could lead to an opioid prescription — and in certain cases, there is potential for development of opioid use disorder (OUD).

That’s why understanding genetic risk is so important. AvertD® empowers patients and healthcare providers with the information they need to make safe, informed decisions about pain management.

Find out more about AvertD®: https://avertdtest.com/